fig5

From: Super-enhancer inhibitors THZ2 and JQ1 reverse temozolomide resistance in glioblastoma by suppressing SE-driven SOX9 expression

Figure 5. THZ2 significantly inhibits subcutaneous GBM tumor growth. (A and B) THZ2 in combination with TMZ inhibits the growth of subcutaneous GBM tumors in nude mice (n = 4); (C) Effects of THZ2 and TMZ on body weight in nude mice; (D) Effects of THZ2, TMZ, or their combination on Ki67 expression in subcutaneous GBM tissue; (E) Histological examination of major organs (heart, liver, spleen, lung, and kidney) in mice treated with THZ2, TMZ, or their combination. Scale bars: 20 μM. Data are presented as mean ± SD from three independent experiments (n = 3). ns: No significant; ^*P < 0.05; ^**P < 0.01; ^***P < 0.001. Statistical significance was assessed using one-way ANOVA. GBM: Glioblastoma; TMZ: temozolomide; SD: standard deviation; ANOVA: analysis of variance.